# EDGAR Filing Document

**Accession Number:** 0001745114
**File Stem:** 0001171843-23-001619
**Filing Date:** 2023-3
**Character Count:** 4404
**Document Hash:** 6c97f3dfe7d52ceff9012016510a5848
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-23-001619.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001171843-23-001619

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230313

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MOLECULAR PARTNERS AG
- **CENTRAL INDEX KEY:** 0001745114
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40488
- **FILM NUMBER:** 23725989

**BUSINESS ADDRESS:**
- **STREET 1:** WAGISTRASSE 14
- **CITY:** Z?RICH-SCHLIEREN
- **STATE:** V8
- **ZIP:** 8952
- **BUSINESS PHONE:** 41 44 755 77 00

**MAIL ADDRESS:**
- **STREET 1:** WAGISTRASSE 14
- **CITY:** Z?RICH-SCHLIEREN
- **STATE:** V8
- **ZIP:** 8952

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of March 2023**

Commission File Number: **001-40488**

**Molecular Partners AG**

(Translation of registrant's name into English)

**Wagistrasse 14 8952 Zurich-Schlieren Switzerland**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ] &nbsp;&nbsp;&nbsp;&nbsp; Form 40-F [ ]

------

On March 13, 2023, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

[(c) Exhibit 99.1. Press release dated March 13, 2023](exh_991.htm)

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | <u>**&nbsp;&nbsp;&nbsp;&nbsp;Molecular Partners AG&nbsp;&nbsp;&nbsp;&nbsp;**</u> |
|  | (Registrant) |
| Date: March 13, 2023 | <u>&nbsp;&nbsp;&nbsp;&nbsp;/s/ PATRICK AMSTUTZ&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  | Patrick Amstutz |
|  | Chief Executive Officer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**Molecular Partners Publishes Invitation to Annual General Meeting 2023**

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- <u>Molecular Partners AG</u> (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2023.

The Annual General Meeting will be held on Tuesday, April 04, 2023, 14.00 CET (doors open at 13.30 CET), at startup space, Wiesenstrasse 10A, 8952 Schlieren, Switzerland.

**<u>Invitation</u>** to the Annual General Meeting 2022 with the corresponding agenda items

**<u>Einladung</u>** zur Generalversammlung 2022 mit den zugehörigen Traktandenpunkten

**Financial calendar**

---

| | |
|:---|:---|
| April 4, 2023 | Annual General Meeting |
| May 11, 2023 | Interim Management Statement Q1 2023 |
| August 24, 2023 | Half-year results 2023 (unaudited) |
| October 26, 2023 | Interim Management Statement Q3 2023 |

---

The latest timing of the above events can always be viewed on the <u>investor section</u> of the website.

**About Molecular Partners AG**

Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and infectious disease and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. <u>www.molecularpartners.com</u>; Find us on Twitter - <u>@MolecularPrtnrs</u>

**For further details, please contact:**

Seth Lewis, Head of Investor Relations & Strategy

Concord, Massachusetts, U.S.

<u>seth.lewis@molecularpartners.com</u>

Tel: +1 781 420 2361

Antonio Ligi, Head of Communications

Zürich-Schlieren, Switzerland

<u>antonio.ligi@molecularpartners.com</u>

Tel: +41 79 723 36 81